The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025.

The FDA approved a new antibiotic for UTIs from drugmaker GSK. The drug, Blujepa, is for women and girls ages 12 and up.

The most commonly reported adverse events in patients taking Blujepa were gastrointestinal, including diarrhea (16 percent) and nausea (9 percent). The maximum severity of these a

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.